Full review
Hyper-Care CAIHL draft report
Evidence-linked HugoScore draft report for a health AI tool that affects patients.
Agency checklist · October 30, 2026
Mixed 5 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Patient data collective and AI advocate design, including research matching and shared commercial value. Operational implementation remains unverified.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | AI that is designed to assist you and keep your health data and interactions confidentialSource Marketing page labels a 'Safe AI Advocate'. No product screen or consent step was seen. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Hyper-Care is named as a Public Benefit Corporation (Values page), but no AI model or model maker is named in any page read. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Register an account, and connect your health dataSource FAQ answer to 'How do I join'. The advocacy-group path ('activates patient community from directory') may differ, and no terms or privacy policy were found. |
| 4. Patient sets the task | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Marketing says 'keeping every decision under your control', but nothing documents that the patient sets what the AI advocate does. The platform is also built around study matching and research revenue. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | Register an account, and connect your health dataSource Self-started tool rule: Q3 is yes and no care depends on it. Source is the Q3 source. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | from spotting trends to explaining your results in plain languageSource Marketing description of the AI advocate output. Not verified in a product. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. No documented route to correct or contest AI output. |
| 8. Patient can get a copy | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Pages say 'You hold the encryption keys' and data sits in personal data pods, but no export or copy route is documented. |
| 9. Patient can delete | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. No deletion route documented in the pages read. |
| 10. Training or sale does not override patient choice | Yes | documented Not independently replicated | No data leaves your secure pod without your explicit, "opt-in" permissionSource The FAQ also says data is not sold 'without your consent'. Model training is not addressed. Marketing only, no binding terms found. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Solid pods are named, but no way to run the tool yourself or move the function elsewhere is documented. |
| 12. No advertising or data business | No | documented Not independently replicated | Life Sciences Pay Us: Companies pay for access to anonymized, high-quality datasets to speed up drug developmentSource Documented data business: the Trust page says they 'monetize aggregated insights' and share revenue with patients. Payment to patients and consent do not change the Q12 rule. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier report
Hyper-Care: CAIHL reassessment
September 8, 2026. Published AI-assisted draft.
Hyper-Care describes patient-controlled record use, sponsor choice, study matching, and shared commercial value. These remain design claims. Key custody, revocation, compensation terms, and access without research participation are not independently established.
Scope and agency posture
Patient data collective and AI advocate design, including research matching and shared commercial value. Operational implementation remains unverified.
Posture: Potentially agency-expanding, with commercialization and disclosure caveats.
Axis: 78/100, retained provisionally. No numerical recalibration was performed.
Sources and documented findings
- The patient page describes AI interpretation, care-team sharing, study matching and compensation, with decisions said to remain under user control. https://hyper-care.org/patients-1
- The trust page claims patient-held keys, explicit opt-in data release, visible sponsors and revenue sharing. It names security frameworks but does not itself provide certification evidence or enforceable compensation terms. https://hyper-care.org/trust-1
Patient authority
Inference from the documented workflow: The described ability to select sponsors and control release is agency-relevant. Payment for contributing data does not itself establish governance rights or permission to refuse research while retaining care tools.
Critical capacity
Editorial assessment: Record explanation and study discovery could support informed action. No reviewed page establishes correction or appeal of an AI inference or an eligibility exclusion.
Informed control
Editorial assessment: Transparency promises are specific but remain promises. Encryption in transit and at rest does not alone establish that only the patient can decrypt data.
Assessment and limits
Keep the potential-design assessment with low-to-medium confidence. Remove the baseline's implication that missing verification mechanically lowers a number. Unverified controls limit confidence rather than proving poor agency.
Confidence: Low to moderate for design claims, low for operational guarantees.
Remaining uncertainty: Key custody, revocation enforcement, navigation without research participation and compensation terms remain unverified
Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.
Review provenance
- Reviewer/model: OpenAI Codex / GPT-6.
- Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
- Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
- Earlier review: 2026-06-30. Historical assessment. Earlier claims are not automatically reverified by this publication.